{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:17:09Z","timestamp":1783063029018,"version":"3.54.6"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Health Systems Research Institute"},{"name":"the Siriraj Core Research Facility (SiCRF) and Strategic Project Grant"},{"name":"the Siriraj Chalermphrakiat Grant"},{"name":"the Thanapat Fund","award":["D003752"],"award-info":[{"award-number":["D003752"]}]},{"name":"the Cancer Precision Medicine Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51731-4","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:56:40Z","timestamp":1777841800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic profiling and therapeutic targets of Thai melanoma revealed by next-generation sequencing"],"prefix":"10.1038","volume":"16","author":[{"given":"Kornyok","family":"Kamdee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manop","family":"Pithukpakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panitta","family":"Sitthinamsuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerapat","family":"Paringkarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janista","family":"Thumrongtharadol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuthinun","family":"Achariyapota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitthichoke","family":"Taweepraditpol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasmon","family":"Chairatchaneeboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"51731_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"51731_CR2","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain, A. H. et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl. J. Med. 373, 1926\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1502583 (2015).","journal-title":"N Engl. J. Med."},{"key":"51731_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/s1470-2045(17)30171-7","volume":"18","author":"M Schreuer","year":"2017","unstructured":"Schreuer, M. et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 18, 464\u2013472. https:\/\/doi.org\/10.1016\/s1470-2045(17)30171-7 (2017).","journal-title":"Lancet Oncol."},{"key":"51731_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2020.04.044","volume":"135","author":"L Si","year":"2020","unstructured":"Si, L. et al. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Eur. J. Cancer. 135, 31\u201338. https:\/\/doi.org\/10.1016\/j.ejca.2020.04.044 (2020).","journal-title":"Eur. J. Cancer"},{"key":"51731_CR5","doi-asserted-by":"publisher","unstructured":"Awada, G. et al. A phase 2 clinical trial of trametinib and low-dose dabrafenib in patients with advanced pretreated NRAS(Q61R\/K\/L) mutant melanoma (TraMel-WT). Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13092010 (2021).","DOI":"10.3390\/cancers13092010"},{"key":"51731_CR6","doi-asserted-by":"publisher","unstructured":"Girod, M. et al. Non-V600E\/K BRAF Mutations in metastatic melanoma: molecular description, frequency, and effectiveness of targeted therapy in a large national cohort. JCO Precision Oncol. e2200075 https:\/\/doi.org\/10.1200\/po.22.00075 (2022).","DOI":"10.1200\/po.22.00075"},{"key":"51731_CR7","doi-asserted-by":"publisher","first-page":"e000341","DOI":"10.1136\/jitc-2019-000341","volume":"8","author":"ND Klemen","year":"2020","unstructured":"Klemen, N. D. et al. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. J. Immunother. Cancer. 8, e000341. https:\/\/doi.org\/10.1136\/jitc-2019-000341 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"51731_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5021\/ad.2014.26.4.485","volume":"26","author":"H Jang","year":"2014","unstructured":"Jang, H. et al. Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. Ann. Dermatol. 26, 485\u2013490. https:\/\/doi.org\/10.5021\/ad.2014.26.4.485 (2014).","journal-title":"Ann. Dermatol."},{"key":"51731_CR9","doi-asserted-by":"publisher","unstructured":"Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl Med. 10 https:\/\/doi.org\/10.1186\/1479-5876-10-85 (2012).","DOI":"10.1186\/1479-5876-10-85"},{"key":"51731_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","volume":"48","author":"L Si","year":"2012","unstructured":"Si, L. et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur. J. Cancer. 48, 94\u2013100. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.056 (2012).","journal-title":"Eur. J. Cancer"},{"key":"51731_CR11","doi-asserted-by":"publisher","first-page":"16607","DOI":"10.1038\/s41598-024-65065-6","volume":"14","author":"DD Jia","year":"2024","unstructured":"Jia, D. D. & Li, T. Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients. Sci. Rep. 14, 16607. https:\/\/doi.org\/10.1038\/s41598-024-65065-6 (2024).","journal-title":"Sci. Rep."},{"key":"51731_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954. https:\/\/doi.org\/10.1038\/nature00766 (2002).","journal-title":"Nature"},{"key":"51731_CR13","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1158\/1078-0432.Ccr-10-2346","volume":"17","author":"Y Kong","year":"2011","unstructured":"Kong, Y. et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin. Cancer Res. 17, 1684\u20131691. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2346 (2011).","journal-title":"Clin. Cancer Res."},{"key":"51731_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175\u2013180. https:\/\/doi.org\/10.1038\/nature22071 (2017).","journal-title":"Nature"},{"key":"51731_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501. https:\/\/doi.org\/10.1038\/nature12912 (2014).","journal-title":"Nature"},{"key":"51731_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756. https:\/\/doi.org\/10.1101\/gr.239244.118 (2018).","journal-title":"Genome Res."},{"key":"51731_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173, 321\u2013337e310. https:\/\/doi.org\/10.1016\/j.cell.2018.03.035 (2018).","journal-title":"Cell"},{"key":"51731_CR18","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1038\/s41467-020-19342-3","volume":"11","author":"GT Lang","year":"2020","unstructured":"Lang, G. T. et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nat. Commun. 11, 5679. https:\/\/doi.org\/10.1038\/s41467-020-19342-3 (2020).","journal-title":"Nat. Commun."},{"key":"51731_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002 (2017).","journal-title":"J. Mol. Diagn."},{"key":"51731_CR20","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani, R. et al. Genomic Classification of Cutaneous Melanoma. Cell 161, 1681\u20131696. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044 (2015).","journal-title":"Cell"},{"key":"51731_CR21","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1158\/2159-8290.Cd-22-0603","volume":"12","author":"F Newell","year":"2022","unstructured":"Newell, F. et al. Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. Cancer Discov. 12, 2856\u20132879. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-0603 (2022).","journal-title":"Cancer Discov"},{"key":"51731_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41467-018-08081-1","volume":"10","author":"K Wong","year":"2019","unstructured":"Wong, K. et al. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat. Commun. 10, 353. https:\/\/doi.org\/10.1038\/s41467-018-08081-1 (2019).","journal-title":"Nat. Commun."},{"key":"51731_CR23","doi-asserted-by":"publisher","first-page":"e70360","DOI":"10.1002\/cam4.70360","volume":"13","author":"T Hida","year":"2024","unstructured":"Hida, T. et al. Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan. Cancer Med. 13, e70360. https:\/\/doi.org\/10.1002\/cam4.70360 (2024).","journal-title":"Cancer Med."},{"key":"51731_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/1346-8138.16579","volume":"49","author":"YJ Chiu","year":"2022","unstructured":"Chiu, Y. J. et al. Genomic profiling with whole-exome sequencing revealed distinct mutations and novel pathways in Asian melanoma. J. Dermatol. 49, 1299\u20131309. https:\/\/doi.org\/10.1111\/1346-8138.16579 (2022).","journal-title":"J. Dermatol."},{"key":"51731_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jid.2017.11.017","volume":"138","author":"KR Moon","year":"2018","unstructured":"Moon, K. R. et al. Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features. J. Invest. Dermatology. 138, 933\u2013945. https:\/\/doi.org\/10.1016\/j.jid.2017.11.017 (2018).","journal-title":"J. Invest. Dermatology"},{"key":"51731_CR26","doi-asserted-by":"publisher","unstructured":"Ng, M. F., Simmons, J. L. & Boyle, G. M. Heterogeneity in Melanoma. Cancers (Basel). 14. https:\/\/doi.org\/10.3390\/cancers14123030 (2022).","DOI":"10.3390\/cancers14123030"},{"key":"51731_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s11912-023-01453-x","volume":"25","author":"MC Sergi","year":"2023","unstructured":"Sergi, M. C. et al. Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment. Curr. Oncol. Rep. 25, 1247\u20131258. https:\/\/doi.org\/10.1007\/s11912-023-01453-x (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"51731_CR28","doi-asserted-by":"publisher","first-page":"702287","DOI":"10.3389\/fonc.2021.702287","volume":"11","author":"Y Ma","year":"2021","unstructured":"Ma, Y., Xia, R., Ma, X., Judson-Torres, R. L. & Zeng, H. Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy. Front. Oncol. 11, 702287. https:\/\/doi.org\/10.3389\/fonc.2021.702287 (2021).","journal-title":"Front. Oncol."},{"key":"51731_CR29","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.1038\/s41598-022-13391-y","volume":"12","author":"F Huang","year":"2022","unstructured":"Huang, F. et al. Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Sci. Rep. 12, 9559. https:\/\/doi.org\/10.1038\/s41598-022-13391-y (2022).","journal-title":"Sci. Rep."},{"key":"51731_CR30","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1158\/1078-0432.Ccr-21-3344","volume":"28","author":"Q Shi","year":"2022","unstructured":"Shi, Q. et al. Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations. Clin. Cancer Res. 28, 2690\u20132703. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3344 (2022).","journal-title":"Clin. Cancer Res."},{"key":"51731_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/bjc.2017.384","volume":"118","author":"E Hugdahl","year":"2018","unstructured":"Hugdahl, E., Kalvenes, M. B., Mannelqvist, M., Ladstein, R. G. & Akslen, L. A. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma. Br. J. Cancer. 118, 98\u2013105. https:\/\/doi.org\/10.1038\/bjc.2017.384 (2018).","journal-title":"Br. J. Cancer"},{"key":"51731_CR32","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang, F. W. et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma. Science 339, 957\u2013959. https:\/\/doi.org\/10.1126\/science.1229259 (2013).","journal-title":"Science"},{"key":"51731_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo, W., Wang, H. & Li, C. Signal pathways of melanoma and targeted therapy. Signal. Transduct. Target. Therapy. 6, 424. https:\/\/doi.org\/10.1038\/s41392-021-00827-6 (2021).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"51731_CR34","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","volume":"61","author":"DDM Pham","year":"2020","unstructured":"Pham, D. D. M., Guhan, S. & Tsao, H. KIT and Melanoma: Biological Insights and Clinical Implications. Yonsei Med. J. 61, 562\u2013571. https:\/\/doi.org\/10.3349\/ymj.2020.61.7.562 (2020).","journal-title":"Yonsei Med. J."},{"key":"51731_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40268-024-00475-5","volume":"24","author":"HA Chaudhary","year":"2024","unstructured":"Chaudhary, H. A., Cannon, T. L. & Winer, A. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature. Drugs R D. 24, 395\u2013403. https:\/\/doi.org\/10.1007\/s40268-024-00475-5 (2024).","journal-title":"Drugs R D"},{"key":"51731_CR36","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","volume":"37","author":"KL Rock","year":"2016","unstructured":"Rock, K. L., Reits, E. & Neefjes, J. Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 37, 724\u2013737. https:\/\/doi.org\/10.1016\/j.it.2016.08.010 (2016).","journal-title":"Trends Immunol."},{"key":"51731_CR37","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell, F. et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat. Commun. 10, 3163. https:\/\/doi.org\/10.1038\/s41467-019-11107-x (2019).","journal-title":"Nat. Commun."},{"key":"51731_CR38","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152\u20131158. https:\/\/doi.org\/10.1038\/nbt.3344 (2015).","journal-title":"Nat. Biotechnol."},{"key":"51731_CR39","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell, D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359, 582\u2013587. https:\/\/doi.org\/10.1126\/science.aao4572 (2018).","journal-title":"Science"},{"key":"51731_CR40","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1172\/jci129317","volume":"129","author":"YP Xu","year":"2019","unstructured":"Xu, Y. P. et al. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J. Clin. Invest. 129, 4316\u20134331. https:\/\/doi.org\/10.1172\/jci129317 (2019).","journal-title":"J. Clin. Invest."},{"key":"51731_CR41","doi-asserted-by":"publisher","unstructured":"Cheng, M. et al. TET2 promotes tumor antigen presentation and T cell IFN-\u03b3, which is enhanced by vitamin C. JCI Insight. 9 https:\/\/doi.org\/10.1172\/jci.insight.175098 (2024).","DOI":"10.1172\/jci.insight.175098"},{"key":"51731_CR42","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905. https:\/\/doi.org\/10.1038\/nature08822 (2010).","journal-title":"Nature"},{"key":"51731_CR43","doi-asserted-by":"publisher","first-page":"87699","DOI":"10.18632\/oncotarget.21181","volume":"8","author":"C Xu","year":"2017","unstructured":"Xu, C. et al. The prognostic significance of MCL1 copy number gain in esophageal squamous cell carcinoma. Oncotarget 8, 87699\u201387709. https:\/\/doi.org\/10.18632\/oncotarget.21181 (2017).","journal-title":"Oncotarget"},{"key":"51731_CR44","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1158\/1078-0432.Ccr-15-0159","volume":"21","author":"R Sanz-Pamplona","year":"2015","unstructured":"Sanz-Pamplona, R. et al. Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. Clin. Cancer Res. 21, 4709\u20134718. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0159 (2015).","journal-title":"Clin. Cancer Res."},{"key":"51731_CR45","doi-asserted-by":"publisher","first-page":"e2400437","DOI":"10.1200\/po-24-00437","volume":"9","author":"T Noguchi","year":"2025","unstructured":"Noguchi, T. et al. Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan. JCO Precis Oncol. 9, e2400437. https:\/\/doi.org\/10.1200\/po-24-00437 (2025).","journal-title":"JCO Precis Oncol."},{"key":"51731_CR46","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.3390\/cancers17223644","volume":"17","author":"A Kaveti","year":"2025","unstructured":"Kaveti, A., Sullivan, R. J. & Tsao, H. KIT-Mutant Melanoma: Understanding the Pathway to Personalized Therapy. Cancers 17, 3644 (2025).","journal-title":"Cancers"},{"key":"51731_CR47","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1200\/jco.19.00489","volume":"37","author":"C Menzer","year":"2019","unstructured":"Menzer, C. et al. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. J. Clin. Oncol. 37, 3142\u20133151. https:\/\/doi.org\/10.1200\/jco.19.00489 (2019).","journal-title":"J. Clin. Oncol."},{"key":"51731_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/cmr.0000000000000628","volume":"30","author":"LD Guti\u00e9rrez-Casta\u00f1eda","year":"2020","unstructured":"Guti\u00e9rrez-Casta\u00f1eda, L. D., Nova, J. A. & Tovar-Parra, J. D. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review. Melanoma Res. 30, 62\u201370. https:\/\/doi.org\/10.1097\/cmr.0000000000000628 (2020).","journal-title":"Melanoma Res."},{"key":"51731_CR49","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.trecan.2021.04.009","volume":"7","author":"G El Tekle","year":"2021","unstructured":"El Tekle, G. et al. Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends Cancer. 7, 823\u2013836. https:\/\/doi.org\/10.1016\/j.trecan.2021.04.009 (2021).","journal-title":"Trends Cancer"},{"key":"51731_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nrc3929","volume":"15","author":"RC Rao","year":"2015","unstructured":"Rao, R. C. & Dou, Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat. Rev. Cancer. 15, 334\u2013346. https:\/\/doi.org\/10.1038\/nrc3929 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"51731_CR51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421. https:\/\/doi.org\/10.1038\/nature12477 (2013).","journal-title":"Nature"},{"key":"51731_CR52","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.Cd-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha, D. et al. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 10, 1808\u20131825. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0522 (2020).","journal-title":"Cancer Discov"},{"key":"51731_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2 (2017).","journal-title":"Genome Med."},{"key":"51731_CR54","doi-asserted-by":"publisher","first-page":"e200202","DOI":"10.1001\/jamanetworkopen.2020.0202","volume":"3","author":"K Parikh","year":"2020","unstructured":"Parikh, K. et al. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. JAMA Netw. Open. 3, e200202\u2013e200202. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0202 (2020).","journal-title":"JAMA Netw. Open."},{"key":"51731_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365. https:\/\/doi.org\/10.1016\/s1470-2045(20)30445-9 (2020).","journal-title":"Lancet Oncol."},{"key":"51731_CR56","doi-asserted-by":"publisher","unstructured":"Subbiah, V., Solit, D. B., Chan, T. A. & Kurzrock, R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: A decision centered on empowering patients and their physicians. Ann. Oncol. 31, 1115\u20131118. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.002 (2020).","DOI":"10.1016\/j.annonc.2020.07.002"},{"key":"51731_CR57","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ccell.2023.03.017","volume":"41","author":"RSP Huang","year":"2023","unstructured":"Huang, R. S. P., Graf, R. P. & Oxnard, G. R. Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering. Cancer Cell. 41, 819\u2013820. https:\/\/doi.org\/10.1016\/j.ccell.2023.03.017 (2023).","journal-title":"Cancer Cell."},{"key":"51731_CR58","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury, C. A. et al. Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS One. 17, e0264138. https:\/\/doi.org\/10.1371\/journal.pone.0264138 (2022).","journal-title":"PLoS One"},{"key":"51731_CR59","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/cancers15010283","volume":"15","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study. Cancers 15, 283 (2023).","journal-title":"Cancers"},{"key":"51731_CR60","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713. https:\/\/doi.org\/10.1038\/nm.4333 (2017).","journal-title":"Nat. Med."},{"key":"51731_CR61","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.Cd-17-0151","volume":"7","author":"AACR Project GENIE","year":"2017","unstructured":"AACR Project GENIE. Powering Precision Medicine through an International Consortium. Cancer Discov. 7, 818\u2013831. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0151 (2017).","journal-title":"Cancer Discov"},{"key":"51731_CR62","doi-asserted-by":"publisher","unstructured":"Yang, T. T., Yu, S., Ke, C. K. & Cheng, S. T. The Genomic landscape of melanoma and its therapeutic implications. Genes (Basel). 14. https:\/\/doi.org\/10.3390\/genes14051021 (2023).","DOI":"10.3390\/genes14051021"},{"key":"51731_CR63","doi-asserted-by":"publisher","first-page":"726","DOI":"10.21037\/tp-20-102","volume":"9","author":"J Fan","year":"2020","unstructured":"Fan, J., Gao, L., Chen, J. & Hu, S. Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. Transl Pediatr. 9, 726\u2013733. https:\/\/doi.org\/10.21037\/tp-20-102 (2020).","journal-title":"Transl Pediatr."},{"key":"51731_CR64","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.3892\/or.2019.7375","volume":"42","author":"G Yu","year":"2019","unstructured":"Yu, G. et al. Gene mutation profile and risk stratification in AML1\u2013ETO\u2013positive acute myeloid leukemia based on next\u2013generation sequencing. Oncol. Rep. 42, 2333\u20132344. https:\/\/doi.org\/10.3892\/or.2019.7375 (2019).","journal-title":"Oncol. Rep."},{"key":"51731_CR65","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1038\/s41467-022-33351-4","volume":"13","author":"F Ma","year":"2022","unstructured":"Ma, F., Laster, K. & Dong, Z. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat. Commun. 13, 5651. https:\/\/doi.org\/10.1038\/s41467-022-33351-4 (2022).","journal-title":"Nat. Commun."},{"key":"51731_CR66","doi-asserted-by":"publisher","first-page":"11427","DOI":"10.1038\/s41598-025-95834-w","volume":"15","author":"K Kamdee","year":"2025","unstructured":"Kamdee, K. et al. Comprehensive germline and somatic profiling of high-risk Thai breast cancer via next-generation sequencing. Sci. Rep. 15, 11427. https:\/\/doi.org\/10.1038\/s41598-025-95834-w (2025).","journal-title":"Sci. Rep."},{"key":"51731_CR67","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.Can-17-0337","volume":"77","author":"JT Robinson","year":"2017","unstructured":"Robinson, J. T., Thorvaldsd\u00f3ttir, H., Wenger, A. M., Zehir, A. & Mesirov, J. P. Variant Review with the Integrative Genomics Viewer. Cancer Res. 77, e31\u2013e34. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0337 (2017).","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51731-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51731-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51731-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:34:06Z","timestamp":1783060446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51731-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51731"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51731-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Siriraj Hospital Institutional Review Board (COA no. Si 409\/2020) for research involving human participants. Written informed consent was obtained from all participants prior to enrollment, and clinical samples were collected only after approval by the institutional ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"20451"}}